Biopharmaceutical company GSK plc (LSE/NYSE:GSK) announced on Monday that it has reached a confidential settlement with plaintiff Ronald Kimbrow, resolving a case filed in Illinois state court relating to Zantac (ranitidine).

The company does not admit any liability in this agreement.

Citing 16 epidemiological studies looking at human data regarding the use of ranitidine, GSK said the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

GSK added that it will continue to vigorously defend itself against ongoing litigation related to Zantac, prioritising the interests of the company and its shareholders.